Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Summary

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: Be 18 years or older. Have locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Non-Small Cell Lung Cancer
• Non-Small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Non-Small-Cell Lung (NSCLC)
• Metastatic Non Small Cell Lung Cancer
• Lung Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

+63 more sites listed on ClinicalTrials.gov